Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias

Jakob R. Passweg, Marco Rabusin

Research output: Contribution to journalArticlepeer-review

Abstract

Here we summarize data on hematopoietic stem cell transplantation (HSCT) to treat severe, refractory, hematologic autoimmune cytopenia. In the last 10 years, limited experience has been gained with the use of HSCT for hematologic disease. A phase II study by the NIH has presented dataon autologous HSCT in 14 patients with immune thrombocytopenia (ITP) or Evans' syndrome with no early deaths and a response rate of 57%. The registry of the European Group of Blood and Marrow Transplantation holds data on 65 transplants, 37 autologous, 28 allogeneic in 59 patients. Disease entities and regimens used were heterogeneous. Patients had autoimmune hemolytic anemia, Evans' syndrome; ITP, pure red cell aplasia, pure white cell aplasia, or thrombotic thrombocytopenic purpura. Patients had longstanding disease having failed multiple prior treatments. Among 36 evaluable patients with a first autologous HSCT, 3 died of treatment-related causes, 4 died of disease progression, 12 were nonresponders, 7 patients had transient responses and 9 had sustained partial or complete remission. Of the 23 patients with a first allogeneic HSCT 5 died of treatment-related complications, 4 died of progressive disease and all but 2 of the remaining patients had a sustained response. Autologous and allogeneic HSCT may induce response in a considerable proportion of patients with autoimmune cytopenia of long duration.

Original languageEnglish
Pages (from-to)660-665
Number of pages6
JournalAutoimmunity
Volume41
Issue number8
DOIs
Publication statusPublished - 2008

Keywords

  • Allogeneic
  • Autoimmune cytopenia
  • Autologous
  • Immune thrombocytopenia
  • Pure red cell aplasia
  • Stem cell transplantation

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias'. Together they form a unique fingerprint.

Cite this